Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anticancer monoclonal antibodies - Recepta biopharma

Next Previous
Drug Profile

Research programme: anticancer monoclonal antibodies - Recepta biopharma

Alternative Names: Anti-LeB antibody; mAb 58-1066; mAb A34; mAb MX35; Monoclonal antibody 58-1066 - Anti-LeB; Monoclonal antibody A34 (209-342); Monoclonal antibody MX35; RebmAb-300; RebmAb-400; RebmAb-500

Latest Information Update: 11 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ludwig Institute for Cancer Research
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Lewis blood group system modulators; Type-IIb sodium-phosphate cotransporter protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Jan 2023 Preclinical development is still ongoing for Cancer in Brazil (http://www.receptabio.com.br/en/pesquisa-desenvolvimento/anticorpos-monoclonais-recepta-detem-potencial-para-tratar-diversos-tipos-de-cancer/)
  • 28 Oct 2020 No recent reports of development identified for preclinical development in Cancer in Brazil
  • 23 Oct 2018 Preclinical development is ongoing in Brazil (Recepta biopharma pipeline, October 2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top